Mylan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 120.00 Cr
as on 28-07-2024
- Paid Up Capital ₹ 10.00 Cr
as on 28-07-2024
- Company Age 27 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -48.29%
(FY 2023)
- Profit -109.59%
(FY 2023)
- Ebitda -91.39%
(FY 2023)
- Net Worth -20.58%
(FY 2023)
- Total Assets 16.57%
(FY 2023)
About Mylan Pharmaceuticals
The Corporate was formerly known as Mylan Development Centre Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 120.00 Cr and a paid-up capital of Rs 10.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Mylan Pharmaceuticals Private Limited India is Rekha Lakhotiya as COMPANY SECRETARY. Ajay Rathore and Praveen Chauhan serve as directors at the Company.
- CIN/LLPIN
U73100TG1997PTC149781
- Company No.
106267
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Mar 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Mylan Pharmaceuticals Private Limited offer?
Mylan Pharmaceuticals Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antifungal Injection, Tablet & Syrup, Antiviral Drugs, Health Care Service, Favipiravir Tablet, Women Care, Feminine Hygiene.
Who are the key members and board of directors at Mylan Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rekha Lakhotiya  | Company Secretary | 03-Dec-2015 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ajay Rathore | Whole-Time Director | 21-Jun-2019 | Current |
| Praveen Chauhan | Additional Director | 22-Apr-2024 | Current |
Financial Performance and Corporate Structure Insights of Mylan Pharmaceuticals.
Mylan Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 48.29% decrease. The company also saw a substantial fall in profitability, with a 109.59% decrease in profit. The company's net worth observed a substantial decline by a decrease of 20.58%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mylan Pharmaceuticals?
In 2023, Mylan Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mylan Pharmaceuticals?
Mylan Pharmaceuticals has a workforce of 3092 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mylan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mylan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
